1 INTRODUCTION (Page No. - 21)

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 MARKET SCOPE

1.4 YEARS CONSIDERED FOR THE STUDY

1.5 CURRENCY

1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY (Page No. - 24)

2.1 RESEARCH DATA

2.2 SECONDARY DATA

2.2.1 SECONDARY SOURCES

2.3 PRIMARY DATA

2.3.1 KEY DATA FROM PRIMARY SOURCES

2.4 MARKET SIZE ESTIMATION

2.4.1 BOTTOM-UP APPROACH

2.4.2 GROWTH FORECAST

2.4.3 TOP-DOWN APPROACH

2.5 MARKET BREAKDOWN AND DATA TRIANGULATION

2.6 ASSUMPTIONS FOR THE STUDY

2.7 LIMITATIONS

3 EXECUTIVE SUMMARY (Page No. - 31)

4 PREMIUM INSIGHTS (Page No. - 34)

4.1 BIOSIMILARS MARKET OVERVIEW

4.2 NORTH AMERICA: BIOSIMILARS MARKET,BY PRODUCT,2019

4.3 GEOGRAPHICAL SNAPSHOT OF THE BIOSIMILARS MARKET

5 REGULATORY OUTLOOK (Page No. - 37)

5.1 NORTH AMERICA

5.1.1 US

5.1.2 CANADA

5.2 EUROPE

5.3 ASIA PACIFIC

5.3.1 CHINA

5.3.2 INDIA

5.3.3 JAPAN

5.3.4 SOUTH KOREA

5.3.5 AUSTRALIA

5.4 REST OF THE WORLD

5.4.1 BRAZIL

5.4.2 MEXICO

5.4.3 ARGENTINA

5.4.4 SAUDI ARABIA

6 MARKET OVERVIEW (Page No. - 42)

6.1 INTRODUCTION

6.2 MARKET DYNAMICS

6.2.1 DRIVERS

6.2.1.1 Increasing demand for biosimilar drugs

6.2.1.2 Rising incidence of chronic diseases

6.2.2 RESTRAINTS

6.2.2.1 Complexities in manufacturing

6.2.2.2 Resistance from biologic manufacturers

6.2.3 OPPORTUNITIES

6.2.3.1 Emerging markets

6.2.3.2 New indications and the patent expiry of biologic products

6.2.4 CHALLENGES

6.2.4.1 Stringent regulatory requirements

6.2.5 TRENDS

6.2.5.1 Collaborations for biosimilar research and clinical trials

7 BIOSIMILARS MARKET,BY PRODUCT (Page No. - 48)

7.1 INTRODUCTION

7.2 MONOCLONAL ANTIBODIES

7.2.1 INFLIXIMAB

7.2.1.1 Infliximab accounted for the largest share of the monoclonal antibodies market

7.2.2 RITUXIMAB

7.2.2.1 Rising incidence of autoimmune diseases and cancer are key drivers of market growth

7.2.3 TRASTUZUMAB

7.2.3.1 Rising incidences of cancer will drive market growth

7.2.4 ADALIMUMAB

7.2.4.1 Adalimumab will register the highest CAGR in the monoclonal antibodies market

7.2.5 OTHER MONOCLONAL ANTIBODIES

7.3 INSULIN

7.3.1 INCREASING INCIDENCE OF DIABETES WILL SUPPORT MARKET GROWTH

7.4 GRANULOCYTE COLONY-STIMULATING FACTOR

7.5 ERYTHROPOIETIN

7.5.1 RISING INCIDENCE OF BLOOD DISORDERS WILL DRIVE MARKET GROWTH

7.6 RECOMBINANT HUMAN GROWTH HORMONE

7.6.1 MARKET GROWTH IS DRIVEN PRIMARILY BY THE INCREASING INCIDENCE OF GROWTH DEFICIENCY DISORDERS

7.7 ETANERCEPT

7.7.1 APAC MARKET FOR ETANERCEPT WILL SHOW THE HIGHEST GROWTH IN THE FORECAST PERIOD

7.8 FOLLITROPIN

7.8.1 INCREASING APPLICATION OF FOLLITROPIN IN INFERTILITY TREATMENT WILL DRIVE MARKET GROWTH

7.9 TERIPARATIDE

7.9.1 INCREASING INCIDENCE OF OSTEOPOROSIS IS THE MAIN GROWTH DRIVER FOR THIS MARKET

7.10 INTERFERONS

7.10.1 MARKET GROWTH IS SUPPORTED BY THE RISING INCIDENCE OF INFECTIOUS DISEASES

7.11 ENOXAPARIN SODIUM

7.11.1 WIDE RANGE OF APPLICATIONS HAVE SUPPORTED THE DEMAND FOR ENOXAPARIN SODIUM BIOSIMILARS

7.12 GLUCAGON

7.12.1 SANDOZ IS A MAJOR PLAYER IN THE GLUCAGON BIOSIMILARS MARKET

7.13 CALCITONIN

7.13.1 INCREASING INCIDENCE OF OSTEOPOROSIS WILL DRIVE THE MARKET

8 BIOSIMILARS MARKET,BY TYPE OF MANUFACTURING (Page No. - 63)

8.1 INTRODUCTION

8.2 IN-HOUSE MANUFACTURING

8.2.1 COST-EFFECTIVENESS MAKES IN-HOUSE MANUFACTURING HIGHLY PREFERABLE FOR MOST MARKET PLAYERS

8.3 CONTRACT MANUFACTURING

8.3.1 OUTSOURCING PRODUCTION ENABLES COMPANIES TO FOCUS ON CORE COMPETENCY AND PROVIDES COST-BENEFITS

9 BIOSIMILARS MARKET,BY INDICATION (Page No. - 67)

9.1 INTRODUCTION

9.2 ONCOLOGY

9.2.1 RISING BURDEN OF CANCER AND GROWING INCIDENCE HAVE DRIVEN DEMAND FOR BIOSIMILARS

9.3 CHRONIC DISEASES

9.3.1 HIGH EFFICACY OF BIOSIMILARS HAS DRIVEN RESEARCH INTO APPLICATIONS IN CHRONIC DISEASE TREATMENT

9.4 AUTOIMMUNE DISEASES

9.4.1 GROWING RESEARCH ACTIVITY FOR AUTOIMMUNE DISEASE INDICATIONS WILL FAVOR MARKET GROWTH

9.5 BLOOD DISORDERS

9.5.1 POSSIBILITY OF COST-REDUCTIONS IN BLOOD DISORDER TREATMENT WILL SUPPORT MARKET DEMAND FOR BIOSIMILARS

9.6 GROWTH HORMONE DEFICIENCY

9.6.1 GROWING CASES OF GH DEFICIENCY DRIVES DEMAND FOR BIOSIMILARS

9.7 INFECTIOUS DISEASES

9.7.1 ASIA PACIFIC SHOWS HIGHEST DEMAND FOR BIOSIMILARS IN THIS SEGMENT

9.8 OTHER INDICATIONS

10 BIOSIMILARS MARKET,BY REGION (Page No. - 78)

10.1 INTRODUCTION

10.2 EUROPE

10.2.1 UK

10.2.1.1 The UK holds the largest share of the biosimilars market in Europe

10.2.2 FRANCE

10.2.2.1 Rising geriatric population will drive market growth

10.2.3 GERMANY

10.2.3.1 The presence of a favorable pricing system has supported biosimilar adoption in Germany

10.2.4 ITALY

10.2.4.1 Rising geriatric population in Italy will support market growth

10.2.5 SPAIN

10.2.5.1 R&D investments for the development of innovative drugs is a key growth driver in the Spanish market

10.2.6 REST OF EUROPE

10.3 ASIA PACIFIC

10.3.1 INDIA

10.3.1.1 India holds the largest share of the APAC market

10.3.2 CHINA

10.3.2.1 China accounts for the second-largest share of the APAC market

10.3.3 SOUTH KOREA

10.3.3.1 Rising incidences of chronic diseases are expected to drive the market in South Korea

10.3.4 JAPAN

10.3.4.1 Growing geriatric population is expected to drive the market in Japan

10.3.5 AUSTRALIA

10.3.5.1 Increasing number of product launches will drive market growth

10.3.6 REST OF ASIA PACIFIC

10.4 NORTH AMERICA

10.4.1 US

10.4.1.1 US will dominate the North American biosimilars market

10.4.2 CANADA

10.4.2.1 Increasing incidences of chronic diseases will drive market growth in Canada

10.5 LATIN AMERICA

10.5.1 RISING INCIDENCES OF CANCER WILL DRIVE MARKET GROWTH

10.6 MIDDLE EAST AND AFRICA

10.6.1 FAVORABLE HEALTHCARE REFORMS AND INFRASTRUCTURAL DEVELOPMENT WILL FAVOR MARKET GROWTH

11 COMPETITIVE LANDSCAPE (Page No. - 137)

11.1 OVERVIEW

11.2 MARKET SHARE ANALYSIS,2018

11.3 COMPETITIVE SCENARIO

11.3.1 PRODUCT LAUNCHES AND APPROVALS

11.3.2 PARTNERSHIPS,COLLABORATIONS,AND AGREEMENTS

11.3.3 ACQUISITIONS

11.3.4 EXPANSIONS

11.4 COMPETITIVE LEADERSHIP MAPPING (2018)

11.4.1 VENDOR INCLUSION CRITERIA

11.4.2 VISIONARY LEADERS

11.4.3 INNOVATORS

11.4.4 DYNAMIC DIFFERENTIATORS

11.4.5 EMERGING COMPANIES

12 COMPANY PROFILES (Page No. - 143)

(Business overview,Products offered,Recent developments,Product pipeline & MnM View)*

12.1 SANDOZ

12.2 PFIZER

12.3 ELI LILLY

12.4 TEVA PHARMACEUTICAL

12.5 CELLTRION

12.6 BIOCON

12.7 AMGEN

12.8 SAMSUNG BIOLOGICS

12.9 MYLAN

12.10 DR. REDDY�S LABORATORIES

12.11 STADA ARZNEIMITTEL AG

12.12 COHERUS BIOSCIENCES

12.13 BIOCAD

12.14 AMEGA BIOTECH

12.15 PROBIOMED

12.16 BOEHRINGER INGELHEIM

12.17 APOTEX

12.18 FRESENIUS KABI

12.19 GEDEON RICHTER

12.20 MABXIENCE

*Details on Business overview,Products offered,Recent developments,Product pipeline & MnM View might not be captured in case of unlisted companies

13 APPENDIX (Page No. - 178)

13.1 INSIGHTS OF INDUSTRY EXPERTS

13.2 DISCUSSION GUIDE

13.3 KNOWLEDGE STORE: MARKETSANDMARKETS� SUBSCRIPTION PORTAL

13.4 AVAILABLE CUSTOMIZATIONS

13.5 RELATED REPORTS

13.6 AUTHOR DETAILS



LIST OF TABLES (133 Tables)

TABLE 1 STATUS OF REGULATORY PATHWAY IN NORTH AMERICA

TABLE 2 SUBSTITUTION STATUS IN EUROPEAN COUNTRIES

TABLE 3 STATUS OF REGULATORY PATHWAY IN THE ASIA PACIFIC

TABLE 4 STATUS OF REGULATORY PATHWAY IN ROW COUNTRIES

TABLE 5 LIST OF KEY BIOLOGICS UNDER THE THREAT OF PATENT EXPIRY

TABLE 6 MAJOR COLLABORATIONS IN THE BIOSIMILARS MARKET (2017�2020)

TABLE 7 BIOSIMILARS MARKET,BY PRODUCT,2018�2025 (USD MILLION)

TABLE 8 BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,BY TYPE,2018�2025 (USD MILLION)

TABLE 9 US: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,BY TYPE,2018�2025 (UNITS)

TABLE 10 BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,BY REGION,2018�2025 (USD MILLION)

TABLE 11 BIOSIMILARS MARKET FOR INFLIXIMAB,BY REGION,2018�2025 (USD MILLION)

TABLE 12 BIOSIMILARS MARKET FOR RITUXIMAB,BY REGION,2018�2025 (USD MILLION)

TABLE 13 BIOSIMILARS MARKET FOR TRASTUZUMAB,BY REGION,2018�2025 (USD MILLION)

TABLE 14 BIOSIMILARS MARKET FOR ADALIMUMAB,BY REGION,2018�2025 (USD MILLION)

TABLE 15 BIOSIMILARS MARKET FOR OTHER MONOCLONAL ANTIBODIES,BY REGION,2018�2025 (USD MILLION)

TABLE 16 BIOSIMILARS MARKET FOR INSULIN,BY REGION,2018�2025 (USD MILLION)

TABLE 17 LIST OF APPROVED BIOSIMILARS FOR G-CSF

TABLE 18 BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR,BY REGION,2018�2025 (USD MILLION)

TABLE 19 LIST OF APPROVED BIOSIMILARS FOR ERYTHROPOIETIN

TABLE 20 BIOSIMILARS MARKET FOR ERYTHROPOIETIN,BY REGION,2018�2025 (USD MILLION)

TABLE 21 BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE,BY REGION,2018�2025 (USD MILLION)

TABLE 22 BIOSIMILARS MARKET FOR ETANERCEPT,BY REGION,2018�2025 (USD MILLION)

TABLE 23 BIOSIMILARS MARKET FOR FOLLITROPIN,BY REGION,2018�2025 (USD MILLION)

TABLE 24 BIOSIMILARS MARKET FOR TERIPARATIDE,BY REGION,2018�2025 (USD MILLION)

TABLE 25 BIOSIMILARS MARKET FOR INTERFERONS,BY REGION,2018�2025 (USD MILLION)

TABLE 26 BIOSIMILARS MARKET FOR ENOXAPARIN SODIUM,BY REGION,2018�2025 (USD MILLION)

TABLE 27 BIOSIMILARS MARKET FOR GLUCAGON,BY REGION,2018�2025 (USD MILLION)

TABLE 28 BIOSIMILARS MARKET FOR CALCITONIN,BY REGION,2018�2025 (USD MILLION)

TABLE 29 BIOSIMILARS MARKET,BY TYPE OF MANUFACTURING,2018�2025 (USD MILLION)

TABLE 30 BIOSIMILARS MARKET FOR IN-HOUSE MANUFACTURING,BY REGION,2016�2023 (USD MILLION)

TABLE 31 BIOSIMILARS MARKET FOR CONTRACT MANUFACTURING,BY REGION,2018�2025 (USD MILLION)

TABLE 32 BIOSIMILARS MARKET,BY INDICATION,2018�2025 (USD MILLION)

TABLE 33 BIOSIMILARS APPROVED BY THE US FDA FOR ONCOLOGICAL INDICATIONS,2017�2019

TABLE 34 BIOSIMILARS MARKET FOR ONCOLOGY,BY REGION,2018�2025 (USD MILLION)

TABLE 35 BIOSIMILARS MARKET FOR CHRONIC DISEASES,BY REGION,2018�2025 (USD MILLION)

TABLE 36 BIOSIMILARS APPROVED BY THE US FDA FOR CHRONIC DISEASES,2017�2019

TABLE 37 BIOSIMILARS MARKET FOR AUTOIMMUNE DISEASES,BY REGION,2018�2025 (USD MILLION)

TABLE 38 BIOSIMILARS MARKET FOR BLOOD DISORDERS,BY REGION,2018�2025 (USD MILLION)

TABLE 39 BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY,BY REGION,2018�2025 (USD MILLION)

TABLE 40 BIOSIMILARS MARKET FOR INFECTIOUS DISEASES,BY REGION,2018�2025 (USD MILLION)

TABLE 41 BIOSIMILARS MARKET FOR OTHER INDICATIONS,BY REGION,2018�2025 (USD MILLION)

TABLE 42 BIOSIMILARS MARKET,BY REGION,2018�2025 (USD MILLION)

TABLE 43 LIST OF BIOSIMILARS APPROVED IN EUROPE

TABLE 44 EUROPE: BIOSIMILARS MARKET,BY COUNTRY,2018�2025 (USD MILLION)

TABLE 45 EUROPE: BIOSIMILARS MARKET,BY PRODUCT,2018�2025 (USD MILLION)

TABLE 46 EUROPE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,BY TYPE,2018�2025 (USD MILLION)

TABLE 47 EUROPE: BIOSIMILARS MARKET,BY TYPE OF MANUFACTURING,2018�2025 (USD MILLION)

TABLE 48 EUROPE: BIOSIMILARS MARKET,BY INDICATION,2018�2025 (USD MILLION)

TABLE 49 LIST OF BIOSIMILARS IN THE UK

TABLE 50 UK: BIOSIMILARS MARKET,BY PRODUCT,2018�2025 (USD MILLION)

TABLE 51 UK: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,BY TYPE,2018�2025 (USD MILLION)

TABLE 52 UK: BIOSIMILARS MARKET,BY TYPE OF MANUFACTURING,2018�2025 (USD MILLION)

TABLE 53 UK: BIOSIMILARS MARKET,BY INDICATION,2018�2025 (USD MILLION)

TABLE 54 FRANCE: BIOSIMILARS MARKET,BY PRODUCT,2018�2025 (USD MILLION)

TABLE 55 FRANCE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,BY TYPE,2018�2025 (USD MILLION)

TABLE 56 FRANCE: BIOSIMILARS MARKET,BY TYPE OF MANUFACTURING,2018�2025 (USD MILLION)

TABLE 57 FRANCE: BIOSIMILARS MARKET,BY INDICATION,2018�2025 (USD MILLION)

TABLE 58 LIST OF BIOSIMILARS APPROVED IN GERMANY

TABLE 59 GERMANY: BIOSIMILARS MARKET,BY PRODUCT,2018�2025 (USD MILLION)

TABLE 60 GERMANY: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,BY TYPE,2018�2025 (USD MILLION)

TABLE 61 GERMANY: BIOSIMILARS MARKET,BY TYPE OF MANUFACTURING,2018�2025 (USD MILLION)

TABLE 62 GERMANY: BIOSIMILARS MARKET,BY INDICATION,2018�2025 (USD MILLION)

TABLE 63 ITALY: BIOSIMILARS MARKET,BY PRODUCT,2018�2025 (USD MILLION)

TABLE 64 ITALY: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,BY TYPE,2018�2025 (USD MILLION)

TABLE 65 ITALY: BIOSIMILARS MARKET,BY TYPE OF MANUFACTURING,2018�2025 (USD MILLION)

TABLE 66 ITALY: BIOSIMILARS MARKET,BY INDICATION,2018�2025 (USD MILLION)

TABLE 67 SPAIN: BIOSIMILARS MARKET,BY PRODUCT,2018�2025 (USD MILLION)

TABLE 68 SPAIN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,BY TYPE,2018�2025 (USD MILLION)

TABLE 69 SPAIN: BIOSIMILARS MARKET,BY TYPE OF MANUFACTURING,2018�2025 (USD MILLION)

TABLE 70 SPAIN: BIOSIMILARS MARKET,BY INDICATION,2018�2025 (USD MILLION)

TABLE 71 ROE: BIOSIMILARS MARKET,BY PRODUCT,2018�2025 (USD MILLION)

TABLE 72 ROE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,BY TYPE,2018�2025 (USD MILLION)

TABLE 73 ROE: BIOSIMILARS MARKET,BY TYPE OF MANUFACTURING,2018�2025 (USD MILLION)

TABLE 74 ROE: BIOSIMILARS MARKET,BY INDICATION,2018�2025 (USD MILLION)

TABLE 75 ASIA PACIFIC: BIOSIMILARS MARKET,BY COUNTRY,2018�2025 (USD MILLION)

TABLE 76 ASIA PACIFIC: BIOSIMILARS MARKET,BY PRODUCT,2018�2025 (USD MILLION)

TABLE 77 ASIA PACIFIC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,BY TYPE,2018�2025 (USD MILLION)

TABLE 78 ASIA PACIFIC: BIOSIMILARS MARKET,BY TYPE OF MANUFACTURING,2018�2025 (USD MILLION)

TABLE 79 ASIA PACIFIC: BIOSIMILARS MARKET,BY INDICATION,2018�2025 (USD MILLION)

TABLE 80 BIOSIMILARS APPROVED AND MARKETED IN INDIA

TABLE 81 INDIA: BIOSIMILARS MARKET,BY PRODUCT,2018�2025 (USD MILLION)

TABLE 82 INDIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,BY TYPE,2018�2025 (USD MILLION)

TABLE 83 INDIA: BIOSIMILARS MARKET,BY TYPE OF MANUFACTURING,2018�2025 (USD MILLION)

TABLE 84 INDIA: BIOSIMILARS MARKET,BY INDICATION,2018�2025 (USD MILLION)

TABLE 85 BIOSIMILARS APPROVED IN CHINA

TABLE 86 CHINA: BIOSIMILARS MARKET,BY PRODUCT,2018�2025 (USD MILLION)

TABLE 87 CHINA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,BY TYPE,2018�2025 (USD MILLION)

TABLE 88 CHINA: BIOSIMILARS MARKET,BY TYPE OF MANUFACTURING,2018�2025 (USD MILLION)

TABLE 89 CHINA: BIOSIMILARS MARKET,BY INDICATION,2018�2025 (USD MILLION)

TABLE 90 LIST OF BIOSIMILARS APPROVED IN SOUTH KOREA

TABLE 91 SOUTH KOREA: BIOSIMILARS MARKET,BY PRODUCT,2018�2025 (USD MILLION)

TABLE 92 SOUTH KOREA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,BY TYPE,2018�2025 (USD MILLION)

TABLE 93 SOUTH KOREA: BIOSIMILARS MARKET,BY TYPE OF MANUFACTURING,2018�2025 (USD MILLION)

TABLE 94 SOUTH KOREA: BIOSIMILARS MARKET,BY INDICATION,2018�2025 (USD MILLION)

TABLE 95 LIST OF BIOSIMILARS APPROVED IN JAPAN

TABLE 96 JAPAN: BIOSIMILARS MARKET,BY PRODUCT,2018�2025 (USD MILLION)

TABLE 97 JAPAN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,BY TYPE,2018�2025 (USD MILLION)

TABLE 98 JAPAN: BIOSIMILARS MARKET,BY TYPE OF MANUFACTURING,2018�2025 (USD MILLION)

TABLE 99 JAPAN: BIOSIMILARS MARKET,BY INDICATION,2018�2025 (USD MILLION)

TABLE 100 LIST OF BIOSIMILARS APPROVED IN AUSTRALIA

TABLE 101 AUSTRALIA: BIOSIMILARS MARKET,BY PRODUCT,2018�2025 (USD MILLION)

TABLE 102 AUSTRALIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,BY TYPE,2018�2025 (USD MILLION)

TABLE 103 AUSTRALIA: BIOSIMILARS MARKET,BY TYPE OF MANUFACTURING,2018�2025 (USD MILLION)

TABLE 104 AUSTRALIA: BIOSIMILARS MARKET,BY INDICATION,2018�2025 (USD MILLION)

TABLE 105 LIST OF BIOSIMILARS APPROVED IN NEW ZEALAND

TABLE 106 LIST OF BIOSIMILARS APPROVED IN MALAYSIA

TABLE 107 LIST OF BIOSIMILARS APPROVED IN SINGAPORE

TABLE 108 ROAPAC: BIOSIMILARS MARKET,BY PRODUCT,2018�2025 (USD MILLION)

TABLE 109 ROAPAC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,BY TYPE,2018�2025 (USD MILLION)

TABLE 110 ROAPAC: BIOSIMILARS MARKET,BY TYPE OF MANUFACTURING,2018�2025 (USD MILLION)

TABLE 111 ROAPAC: BIOSIMILARS MARKET,BY INDICATION,2018�2025 (USD MILLION)

TABLE 112 NORTH AMERICA: BIOSIMILARS MARKET,BY COUNTRY,2018�2025 (USD MILLION)

TABLE 113 NORTH AMERICA: BIOSIMILARS MARKET,BY PRODUCT,2018�2025 (USD MILLION)

TABLE 114 NORTH AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,BY TYPE,2018�2025 (USD MILLION)

TABLE 115 NORTH AMERICA: BIOSIMILARS MARKET,BY TYPE OF MANUFACTURING,2018�2025 (USD MILLION)

TABLE 116 NORTH AMERICA: BIOSIMILARS MARKET,BY INDICATION,2018�2025 (USD MILLION)

TABLE 117 LIST OF BIOSIMILARS APPROVED IN THE US

TABLE 118 US: BIOSIMILARS MARKET,BY PRODUCT,2018�2025 (USD MILLION)

TABLE 119 US: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,BY TYPE,2018�2025 (USD MILLION)

TABLE 120 US: BIOSIMILARS MARKET,BY TYPE OF MANUFACTURING,2018�2025 (USD MILLION)

TABLE 121 US: BIOSIMILARS MARKET,BY INDICATION,2018�2025 (USD MILLION)

TABLE 122 LIST OF BIOSIMILARS APPROVED IN CANADA

TABLE 123 CANADA: BIOSIMILARS MARKET,BY PRODUCT,2018�2025 (USD MILLION)

TABLE 124 CANADA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,BY TYPE,2018�2025 (USD MILLION)

TABLE 125 CANADA: BIOSIMILARS MARKET,BY TYPE OF MANUFACTURING,2018�2025 (USD MILLION)

TABLE 126 CANADA: BIOSIMILARS MARKET,BY INDICATION,2018�2025 (USD MILLION)

TABLE 127 LIST OF BIOSIMILARS APPROVED IN LATIN AMERICA

TABLE 128 LATIN AMERICA: BIOSIMILARS MARKET,BY PRODUCT,2018�2025 (USD MILLION)

TABLE 129 LATIN AMERICA: BIOSIMILARS MARKET,BY TYPE OF MANUFACTURING,2018�2025 (USD MILLION)

TABLE 130 LATIN AMERICA: BIOSIMILARS MARKET,BY INDICATION,2018�2025 (USD MILLION)

TABLE 131 MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET,BY PRODUCT,2018�2025 (USD MILLION)

TABLE 132 MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET,BY TYPE OF MANUFACTURING,2018�2025 (USD MILLION)

TABLE 133 MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET,BY INDICATION,2018�2025 (USD MILLION)



LIST OF FIGURES (46 Figures)

FIGURE 1 RESEARCH DESIGN

FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,DESIGNATION,AND REGION

FIGURE 3 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH

FIGURE 4 TOP-DOWN APPROACH

FIGURE 5 DATA TRIANGULATION METHODOLOGY

FIGURE 6 BIOSIMILARS MARKET,BY PRODUCT,2020 VS. 2025 (USD BILLION)

FIGURE 7 BIOSIMILARS MARKET,BY TYPE OF MANUFACTURING,2020 VS. 2025 (USD BILLION)

FIGURE 8 BIOSIMILARS MARKET,BY INDICATION,2020 VS. 2025 (USD MILLION)

FIGURE 9 BIOSIMILARS MARKET,BY REGION,2020 VS. 2025 (USD BILLION)

FIGURE 10 RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE THE GROWTH OF THE MARKET

FIGURE 11 INSULIN HELD LARGEST MARKET SHARE IN 2019

FIGURE 12 CHINA TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD

FIGURE 13 BIOSIMILARS MARKET: DRIVERS,RESTRAINTS,OPPORTUNITIES,& CHALLENGES

FIGURE 14 INCREASING GERIATRIC POPULATION,BY REGION,2019 VS. 2050

FIGURE 15 GLOBAL INCIDENCE OF DIABETES,BY REGION,2019,2030,2045

FIGURE 16 ONCOLOGY SEGMENT TO DOMINATE THE BIOSIMILARS MARKET

FIGURE 17 ARTICLES PUBLISHED ON BIOSIMILARS FOR ONCOLOGY,2010�2018

FIGURE 18 ARTICLES PUBLISHED ON BIOSIMILARS FOR CHRONIC DISEASES,2010�2018

FIGURE 19 ARTICLES PUBLISHED ON BIOSIMILARS FOR AUTOIMMUNE DISEASES,2010�2018

FIGURE 20 ARTICLES PUBLISHED ON BIOSIMILARS FOR BLOOD DISORDERS,2010�2018

FIGURE 21 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH IN THE BIOSIMILARS MARKET DURING THE FORECAST PERIOD

FIGURE 22 EUROPE: BIOSIMILARS MARKET SNAPSHOT

FIGURE 23 ARTICLES ON BIOSIMILAR RESEARCH PUBLISHED IN THE UK,2010�2018

FIGURE 24 ARTICLES ON BIOSIMILAR RESEARCH PUBLISHED IN FRANCE,2010�2018

FIGURE 25 ARTICLES ON BIOSIMILAR RESEARCH PUBLISHED IN GERMANY,2010�2018

FIGURE 26 ARTICLES ON BIOSIMILAR RESEARCH PUBLISHED IN ITALY,2011�2019

FIGURE 27 ARTICLES ON BIOSIMILAR RESEARCH PUBLISHED IN SPAIN,2010�2018

FIGURE 28 ASIA PACIFIC: BIOSIMILARS MARKET SNAPSHOT

FIGURE 29 ARTICLES ON BIOSIMILAR RESEARCH PUBLISHED IN THE US,2010�2018

FIGURE 30 PROJECTED INCREASE IN CANCER INCIDENCE IN CANADA

FIGURE 31 ARTICLES ON BIOSIMILAR RESEARCH PUBLISHED IN CANADA,2010�2018

FIGURE 32 KEY DEVELOPMENTS OF MAJOR PLAYERS FROM 2017 TO 2020

FIGURE 33 GLOBAL BIOSIMILARS MARKET SHARE ANALYSIS,BY KEY PLAYER,2018

FIGURE 34 MNM DIVE-VENDOR COMPARISON MATRIX: BIOSIMILARS MARKET

FIGURE 35 SANDOZ: COMPANY SNAPSHOT

FIGURE 36 PFIZER: COMPANY SNAPSHOT

FIGURE 37 ELI LILLY: COMPANY SNAPSHOT

FIGURE 38 TEVA PHARMACEUTICAL: COMPANY SNAPSHOT

FIGURE 39 CELLTRION: COMPANY SNAPSHOT

FIGURE 40 BIOCON: COMPANY SNAPSHOT

FIGURE 41 AMGEN: COMPANY SNAPSHOT

FIGURE 42 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT

FIGURE 43 MYLAN: COMPANY SNAPSHOT

FIGURE 44 DR. REDDY�S LABORATORIES: COMPANY SNAPSHOT

FIGURE 45 STADA ARZNEIMITTEL: COMPANY SNAPSHOT

FIGURE 46 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT